ZTS Zoetis Inc.
USHealthcareAs of 2026-07-09 09:54
Why ZTS matters now
Zoetis Inc. (ZTS) is a US stock in Healthcare. The latest InvestLog snapshot shows $74.87 with -0.31% on the session and $31.39B in market capitalization; recent performance reads 1-month -0.27% and YTD -37.44%.
The latest financial table shown here is Q1 2026, with revenue of $2.26B, net income of $601.0M, and EPS of $1.42. Investors can compare that operating picture with valuation signals such as P/E 19.74 and FCF yield 6.5%.
The latest indexable market news headline is "ZOETIS INC. (ZTS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Zoetis Inc. Investors of Upcoming Deadline" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $115.00; recent insider activity includes Nayak Abhay U filing ; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
19.74
PEG
2.62
P/B
10.28
P/S
3.47
EV/EBITDA
10.00
DCF Value
$197.35
FCF Yield
6.5%
Div Yield
2.6%
Margins & Returns
Gross Margin
70.8%
Operating Margin
37.6%
Net Margin
27.8%
ROE
62.4%
ROA
17.4%
ROIC
21.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.26B | $601.0M | $1.42 |
| Q4 2025 | $2.39B | $603.0M | $1.37 |
| FY 2025 | $9.47B | $2.67B | $6.02 |
| Q3 2025 | $2.40B | $721.0M | $1.63 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$120.80
Target (Median)
$115.00
Target Range
$95.00 - $160.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.74
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.